$80,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response."
You can find more data on corporate lobbying on Quiver Quantitative.
CHRS Hedge Fund Activity
We have seen 85 institutional investors add shares of CHRS stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,372,853 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $3,369,451
- ALYESKA INVESTMENT GROUP, L.P. added 2,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,802,500
- TWO SIGMA INVESTMENTS, LP added 1,798,126 shares (+356.9%) to their portfolio in Q1 2026, for an estimated $3,038,832
- PROPEL BIO MANAGEMENT, LLC added 1,420,550 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,400,729
- MACQUARIE GROUP LTD removed 899,999 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,277,998
- HUDSON BAY CAPITAL MANAGEMENT LP added 869,980 shares (+104.2%) to their portfolio in Q1 2026, for an estimated $1,470,266
- JANE STREET GROUP, LLC removed 563,016 shares (-93.3%) from their portfolio in Q1 2026, for an estimated $951,497
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CHRS Price Targets
Multiple analysts have issued price targets for $CHRS recently. We have seen 2 analysts offer price targets for $CHRS in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- An analyst from Guggenheim set a target price of $12.0 on 05/11/2026
- Jay Olson from Oppenheimer set a target price of $10.0 on 01/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
